Many highly proliferative cells generate almost all ATP via glycolysis despite abundant O 2 and a normal complement of fully functional mitochondria, a circumstance known as the Crabtree effect. Such anaerobically poised cells are resistant to xenobiotics that impair mitochondrial function, such as the inhibitors rotenone, antimycin, oligomycin, and compounds like carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), that uncouple the respiratory electron transfer system from phosphorylation. These cells are also resistant to the toxicity of many drugs whose deleterious side effect profiles are either caused, or exacerbated, by impairment of mitochondrial function. Drug-induced mitochondrial toxicity is shown by members of important drug classes, including the thiazolidinediones, statins, fibrates, antivirals, antibiotics, and anticancer agents. To increase detection of druginduced mitochondrial effects in a preclinical cell-based assay, HepG2 cells were forced to rely on mitochondrial oxidative phosphorylation rather than glycolysis by substituting galactose for glucose in the growth media. Oxygen consumption doubles in galactose-grown HepG2 cells and their susceptibility to canonical mitochondrial toxicants correspondingly increases. Similarly, toxicity of several drugs with known mitochondrial liabilities is more readily apparent in aerobically poised HepG2 cells compared to glucose-grown cells. Some drugs were equally toxic to both glucoseand galactose-grown cells, suggesting that mitochondrial impairment is likely secondary to other cytotoxic mechanisms.
Many drugs are variously injurious to the liver, cardiovascular system, skeletal muscles, nervous system, and kidneys, among others (Amacher, 2005; Chan et al., 2005; Cote et al., 2006; Malhi et al., 2006; Scatena et al., 2004) . This toxicity is often idiosyncratic and frequently not discovered until a large population of patients has been exposed. Evidence is rapidly accumulating that such negative side effect profiles are attributable to varying extents to deleterious effects on mitochondrial function (Amacher, 2005; Brunmair et al., 2004; Chan et al., 2005; McKee et al., 2006; Wallace and Starkov, 2000) .
In most mammalian cells, mitochondria generate almost all the energy, in the form of ATP, required for survival. Agents that undermine mitochondrial function will correspondingly impair cell viability and, depending on severity, lead to tissue or organ injury. Indeed, several drugs withdrawn from the market because of cytotoxicity to liver (Masubuchi et al., 2006; Ong et al., 2006; Scatena, 2004) and skeletal muscle (Schaefer et al., 2004) have now been found to impair mitochondrial function.
Due to their physiologically relevant metabolic poise (at least under short-term culture conditions), primary cells in culture would be the ideal platform for evaluating potential mitochondrial drug toxicities. However, expense, the technical difficulties associated with isolation, and their brief survival in culture, combine to limit the utility of primary cells in the drug development arena. For these reasons, tumor-derived, immortalized cell lines have become the mainstay of the cell-based assays used in drug discovery and development efforts.
Such cell lines are metabolically adapted for rapid growth under hypoxic and acidic conditions, and they derive almost all of their energy from glycolysis rather than via mitochondrial oxidative phosphorylation (OXPHOS), the Crabtree effect (Rodríguez-Enríquez et al., 2001) . This is the case despite the presence of functionally competent mitochondria, and is due to several factors, including allosteric modulation of glycolytic enzymes (Rodríguez-Enríquez et al., 2001 ) and binding of hexosekinase to mitochondrial porin (Golshani-Hebroni and Bessman, 1997) . In such cells, mitochondrial toxicants have little effect on cell growth or viability, which correspondingly diminishes their utility as predictors of mitochondrial drug liabilities in vivo. Such resistance to perturbed mitochondrial function is exacerbated by contemporary tissue culture practice where cells are typically grown in 25mM glucose, more than fivefold the physiological levels. Despite such limitations, glycolytically poised cell lines have typically been the primary tool for assessment of mitochondrial toxicity.
In this study, we sought to develop a more aerobically poised cultured cell line that retains ease of propagation, yet more reliably reports mitochondrial perturbations. Three propositions are evaluated. First, HepG2 cells are resistant to mitochondrial toxicants due to high glycolytic capacity. Second, HepG2 cells grown in galactose media will increase respiration rates to maintain ATP levels (Warburg et al., 1967) . Oxidation of galactose to pyruvate via glycolysis yields no net ATP, forcing cells to rely on mitochondrial OXPHOS to generate sufficient ATP for survival (Rossignol et al., 2004) . Third, aerobically poised cells oxidizing galactose will be correspondingly more susceptible to mitochondrial toxicants and drugs with known mitochondrial liabilities. To this end, the effects of classical mitochondrial inhibitors on mitochondrial function and ATP synthesis capacity were monitored in HepG2 cells grown under standard high-glucose conditions. These responses were contrasted with those in cells grown in media where glucose had been replaced by galactose and glutamine as the primary oxidizable substrates. The data here indicate that cells grown in galactose are more reliant on OXPHOS, thereby becoming susceptible to mitochondrial toxicants and to drugs with known mitochondrial liabilities. As such, these cells are better suited for assessments of drug-induced mitochondrial dysfunction.
MATERIALS AND METHODS
Materials. All chemicals were purchased from Sigma-Aldrich (St Louis, MO), except bicalutamide, which was purchased at Toronto Research Chemicals Inc. (North York, Ontario, Canada), and were of highest purity available. Cell culture media and supplements were purchased from Invitrogen (Carlsbad, CA), except for fetal bovine serum (FBS) which was purchased from Tissue Culture Biologics (Los Alamitos, CA). Phosphorescent oxygen-sensitive probe, type A65N-1, was from Luxcel Biosciences (Cork, Ireland). Tissue culture flasks (BD Biocoat) and 96-well plates (BD Biocoat) were purchased from VWR (Westchester, PA). CellTiter-Glo Luminescent Cell Viability Assay kits were purchased from Promega (Madison, WI).
Cell culture conditions.
High-glucose media: high-glucose Dulbecco's modified Eagle's medium (DMEM) (Invitrogen 11995-065) containing 25mM glucose and 1mM sodium pyruvate and supplemented with 5mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid (HEPES), 10% FBS, and penicillin-streptomycin (pen-strep; 500 lg/ml final concentration). Galactose media: DMEM deprived of glucose (Invitrogen 11966-025) supplemented with 10mM galactose, 2mM glutamine (6mM final), 5mM HEPES, 10% FBS, 1mM sodium pyruvate, and pen-strep as above. Low-glucose media: DMEM deprived of glucose (Invitrogen 11966-025) supplemented with 5.5mM glucose, 5mM HEPES, 10% FBS, 1mM sodium pyruvate, and pen-strep as above.
HepG2 cells (ATTC, Manassas, VA) were either grown in glucose or galactose-containing media and kept in 5% CO 2 at 37°C. Cells were maintained on collagen-coated 150 cm 2 flasks (356486, BD Biocoat) and seeded onto 96-well plates for individual experiments.
Cell counting. Cells were plated at same densities and allowed to adhere overnight. After 24 and 48 h, cells were stained with trypan blue and counted using a hemocytometer.
Respiration studies. Cells were plated at 300,000 cells/ml or at indicated cell concentrations on collagen-coated, black body, clear bottom 96-well plates, and cells were allowed to adhere overnight. The final media volume was 200 ll. For drug treatments, compound stock solutions were prepared in dimethyl sulfoxide (DMSO) and added to the wells to give the indicated final drug concentrations. Final DMSO concentration was 0.5% vol/vol. Oxygen-sensing probes were then added to each well (10 pmol/well). Finally, 100 ll of heavy mineral oil was added to each well to seal the samples from ambient oxygen, and the plate was placed in a fluorescence plate reader (Safire 2 Tecan) equilibrated at 30°C, and oxygen consumption was monitored over a period of 30 min measuring probe fluorescence signal in each well every 1.5 min in kinetic mode. Instrument settings were 380/650 nm excitation/emission filters, a delay time of 30 ls, a measurement window of 100 ls, and active temperature control of the microplate compartment at 30°C. To ensure gas and temperature equilibration of samples at the start of the assay, all the dispensing steps were carried out at 30°C using prewarmed solutions and a Multi-Blok heater (Barnstead/LabLine, Melrose Park, IL) holding the microplate.
Measurement of cellular ATP content. Cells were plated at 400,000 cells/ ml on collagen-coated, clear 96-well plates. The final media volume was 100 ll. Cellular ATP concentrations were assessed by using the CellTiter-Glo Cell Viability Assay as per manufacturer's instructions. For drug treatments, compound stock solutions were prepared in DMSO and added to the wells to give the indicated final drug concentrations. Final DMSO concentration was 0.5%. Drugs were added 24 h before measurements except during time course experiments. 2-Deoxy-D-glucose (2-DOG) was added to low-glucose media at 10mM where indicated.
Statistical analysis. Comparisons at the indicated concentrations and time points were performed via t-test using Graph Pad Prism software (significance at p < 0.05).
RESULTS

Immortalized Cells Are Resistant to Mitochondrial Toxicants
To examine the response of HepG2 cells to drug-induced mitochondrial dysfunction, cells were treated with the classical mitochondrial inhibitors rotenone (inhibits complex I; nicotinamide adenine dinucleotide hydrogen (NADH)-ubiquinone oxidoreductase), antimycin (inhibits complex III; cytochrome c reductase), oligomycin (inhibits F 1 /F 0 ATPase), and the uncoupler FCCP.
The oxygen consumption of glucose-grown HepG2 cells was assessed in real time for 30 min after treatment at 30°C in a standard 96-well plate using fluorescent oxygen -sensitive probes as described in ''Materials and Methods'' section. Data were transformed to oxygen traces as described by Hynes et al. (2006) . The electron transport system (ETS) inhibitors rotenone, antimycin, and oligomycin were seen to cause immediate and significant mitochondrial inhibition as evidenced by the rapid and severe reduction in cellular oxygen consumption, while treatment with FCCP accelerated cellular oxygen consumption indicative of uncoupling (Fig. 1A) .
Despite this mitochondrial dysfunction, cellular ATP concentrations were not similarly effected in glucose-grown HepG2 cells. Twenty-four hours after treatment, cellular ATP concentrations remained at 45, 60, 70, and 50% with respect to untreated high-glucose-grown cells for rotenone, antimycin, oligomycin, and FCCP-treated cells, respectively ( open bars). Under these low-glucose conditions, used to facilitate analysis of the effect of the competitive glycolysis inhibitor 2-DOG, cellular ATP concentration dropped slightly to 34, 50, and 30% with rotenone, oligomycin, and FCCP, respectively, and even more dramatically with antimycin to 1% (Fig. 1B speckled bars) . Pretreatment with the glycolysis inhibitor 2-DOG in low-glucose media abolished the ability to maintain cellular ATP levels even more dramatically; cellular ATP concentrations dropped to 0, 0, 6, and 5% for rotenone, antimycin, oligomycin, and FCCP-treated cells, respectively, when compared to untreated cells (Fig. 1B solid bars) .
Growing HepG2 Cells in Galactose Increases
Respiration to Maintain ATP The data obtained above support our hypothesis that glucosegrown cells can compensate for mitochondrial impairment by producing the requisite ATP via increased glycolytic flux. To investigate the proposition that cells can be forced to increase reliance on mitochondria for energy generation, we grew cells in the absence of glucose but in the presence of galactose and glutamine. These conditions abolish net yield of ATP from glycolysis and correspondingly increase flux through OXPHOS. Cells were maintained in the galactose media for greater than 10 passages before experiments were conducted. As shown in Figure  2A , the switch in substrate did not cause a change in the growth behavior of the galactose-grown cells when compared to glucosegrown HepG2 cells. Also, ATP content was equivalent in both cell lines (Fig. 2B) . In contrast, respiration rates were increased in the galactose-grown cells (Fig. 2C ). Differences could be discerned at 30,000 cells/ml and were most apparent at a cell concentration of 50,000 cells/ml, where respiration rates were double than those in galactose grown compared to glucose-grown cells (Fig. 2C ).
Cells Relying Predominately on OXPHOS Are More Susceptible to Mitochondrial Inhibitors
To test the proposition that galactose-grown cells are more susceptible to mitochondrial insult, both glucose-and galactose-grown cells were treated with classical inhibitors at increasing concentrations (Fig. 3A) . Time courses were generated over a 24-h period (Fig. 3B) .
The differences in the response between HepG2 cells grown in glucose and those grown in galactose were striking (Fig. 3) . Figure 3A shows the dose-response curves in the presence of rotenone. Cells grown in glucose tolerated up to 1lM rotenone without a significant loss in cell viability. In contrast, cells grown in galactose were highly susceptible with complete loss of viability at 0.1lM. Figure 3B shows a time course for glucose-and galactose-grown cells in the presence of 10lM rotenone. Whereas glucose-grown cells were still >50% viable after 24 h, galactose-grown cells had lost all viability within the first 10 h. Antimycin, oligomycin, and FCCP dramatically reduce ATP in HepG2 cells grown in galactose compared to glucose (Fig. 3) .
Screening Drugs Reveal Mitochondria Toxicity
The last set of experiments were designed to determine whether parallel drug testing in HepG2 cells grown in glucose or galactose could distinguish between primary and secondary mitochondrial toxicity. For this, we exposed both cell lines to drugs with known toxicities, some of which have been reported to have mitochondrial liabilities. We tested the following drugs: nefazodone, flutamide, fenofibrate, nimodipine, risperidone, bicalutimide, tamoxifen, doxorubicin, and imipramide (Figs. 4A-I ). Cells grown in galactose were three-and fourfold more (Figs. 4A and 4B) . Cells showed also a significantly higher sensitivity (1.4-to 2.1-fold) in galactosegrown cells when treated with fenofibrate (Fig. 4C) , nimodipine (Fig. 4D) , bicalutimide (Fig. 4E) and risperidone (Fig. 4F) . Note that concentrations of fenofibrate were increased to account for its higher efficacious Cmax. No difference between glucose-and galactose-grown cells was observed for treatment with tamoxifen (Fig. 4G) , imipramide (Fig. 4H ), or doxorubicin (Fig. 4I) .
DISCUSSION
Deleterious side effect profiles skew risk-benefit considerations for many drugs. For example, the peroxisome proliferatoractivated receptor agonists, such as fibrates and thiazolidinediones, are associated with rare hepatotoxicity, the HMG-CoA reductase inhibitors, such as statins, can induce selective loss of fast-twitch skeletal muscle fibers (rhabdomyolysis), and antibiotics such as the aminoglycosides induce ototoxicity and nephrotoxicity (Wallace and Starkov, 2000) . Antiviral drugs that target viral RNA replication or protein expression concomitantly induce the lipodystrophies and metabolic dysregulation that are the hallmarks of highly active antiretroviral therapy (Cote et al., 2006) .
The evidence is rapidly accumulating that many of the drugs noted above impair mitochondrial function and that such impairment either contributes to or directly underlies the etiology of drug toxicities (Amacher, 2005; Chan et al., 2005; Dykens et al., 2007; Masubuchi et al., 2006) . For example, lipodystrophies and metabolic syndromes in antiviral therapies are attributable to concomitant impairment of mitochondrial DNA replication and expression. Lactic acidosis, a hallmark symptom of mitochondrial failure, forced withdrawal of phenformin, an analog of the currently marketed biguanide metformin (Berger et al., 1976) . Both phenformin and metformin inhibit the mitochondrial electron transfer system by impeding activity of respiratory complex I (Brunmair et al., 2004) , an effect that may well account for some of the therapeutic benefits, such as reduced serum glucose resulting from increased glycolysis to maintain adenylate charge in muscle and other tissues (Owen et al., 2000) . In most instances, tissue toxicity and mitochondrial impairment were only revealed after the drugs were on the market, as in the case of troglitazone (Masubuchi et al., 2006) and cerivastatin (Kaufmann et al., 2006) , both of which were withdrawn from the market. Many, but not all, of the other members of the drug classes noted above also have mitochondrial liabilities (Dykens et al., 2007; Nadanaciva et al., 2007) .
Mitochondrial impairment has often been discovered only late in drug development, even after reaching the market, in some measure because it was not revealed by preclinical cellbased models. To avoid unanticipated mitochondrial impairment and to reduce the possibility of resulting toxicity, cell models are needed that more accurately report mitochondrial effects of drugs and other treatments.
Most cell models routinely found in drug discovery programs use anaerobically poised cell lines derived from tumors. Many of these cell lines contain intact mitochondria, yet have low rates of O 2 consumption that accurately reflect their lack of reliance on OXPHOS, while maintaining elevated rates of glycolysis, the Crabtree effect (Rodríguez-Enríquez et al., 2001) . This metabolic poise is facilitated by standard contemporary cell culture practice where cells are typically grown in supraphysiological glucose conditions of~25mM. Anaerobic glycolysis is inefficient, capturing as ATP only~5-6% of the potential energy in the glucose substrate when fully oxidized via OXPHOS. However, flux rates through the glycolytic pathway can be dramatically accelerated so that inefficiency is offset by an abundance of substrate.
As a result of this anaerobic poise, many transformed cell lines respond minimally, if at all, to various mitochondrial toxicants that are lethal to aerobically poised cells and most primary cells in culture. In this light, it is not surprising that deleterious mitochondrial effects of many xenobiotics and drugs were not discovered in preclinical studies using glycolytic cells.
In order to develop a cell model that more faithfully reports mitochondrial physiology, we forced anaerobically poised HepG2 cells to use OXPHOS by replacing the glucose in the media with galactose and glutamine as the only oxidizable substrates (Rossignol et al., 2004) . Oxidation of galactose to pyruvate yields no net ATP, which impels cells to oxidize pyruvate via OXPHOS to survive. When glucose-grown HepG2 cells are transferred to galactose, O 2 consumption accelerates directly reflecting the metabolic shift toward mitochondrial respiration. Inhibition of glycolysis by 2-DOG is lethal to anaerobically poised low-glucose-grown cells and exacerbates cotreatment with mitochondrial toxicants. Similarly, the electron transport inhibitors rotenone, antimycin, the ATPase (Fig. 3B) . Thus, the latter are better suited to reveal the effects of drug-induced mitochondrial dysfunction on ATP content.
Treatment with a selection of drugs having documented mitochondrial liabilities helped identify both strengths and limitations of the model. For example, nefazodone is much more toxic to galactose-grown cells, in accord with data indicating that it potently inhibits respiration via impairing complex I of the mitochondrial ETS (Nadanaciva et al., 2007) ; 80% of the glucose cells remain viable at a nefazodone concentration that kills 100% of the galactose-grown cells.
Less dramatic differences are seen with flutamide, fenofibrate, and nimodipine, all of which preferentially kill galactosegrown cells at the two or three highest drug concentrations. Fenofibrate and flutamide are both hepatotoxicants and complex I inhibitors (Brunmair et al., 2004; Fau et al., 1994; Gomez et al., 1992) . The L-type Ca 2þ antagonist nimodipine moderates mitochondrial instability in models of N-methyl-D-aspartate excitotoxicity in cell culture (Duzenli et al., 2005) , and in vivo (Rodriguez y Baena et al., 1988), likely via moderation of Ca 2þ influx and resulting improvements in mitochondrial stability. However, it directly effects lipid membranes at higher concentrations (Moring et al., 1990) , and inhibits the mitochondrial Na þ /Ca 2þ exchanger (Palmero et al., 1995) , so it is difficult to parse the various pathways by which it is being toxic here.
Apoptosis induced by the androgen antagonist bicalutamide is receptor mediated (Lin et al., 2006) , and hence a dominant effect at low concentrations, and hepatoxicity is a rare event (Dawson et al., 1997) , in accord with its relative lack of toxicity to galactose-grown cells. The atypical antipsychotic risperidone shows a similar response and has been reported to inhibit complex I in mitochondria isolated from rat liver at high concentrations (Modica-Napolitano et al., 2003) . Hepatotoxicity is also a rare event with risperidone (Krebs et al., 2001) , although mitochondrial failure has been implicated in tardive dyskinesia and other extrapyramidal movement disorders induced by many antipsychotics (Eyles et al., 2000) . In both these cases, although the drugs are not very potent, the toxicity is most readily apparent in the galactose-grown cells.
Tamoxifen, imipramine, and doxorubicin are equally toxic to both glucose-and galactose-grown cells. Although all three drugs are known to have deleterious effects on mitochondrial function, the proximate mediator of their cytotoxicity is not necessarily such impairment. For example, estrogen receptor mediated responses of tamoxifen dominate at low concentrations, whereas nonspecific interactions arise at higher concentrations (Cardoso et al., 2001) . In accord with the data here, tamoxifen is reported to both inhibit and uncouple mitochondrial respiration at concentrations above 20 nmol/mg mitochondrial protein (Cardoso et al., 2001; Hynes et al., 2006) , concentrations at which direct destabilization of membrane integrity not only in mitochondria, but also in other cell membranes, becomes apparent (Cruz Silva et al., 2000) . In this way, at elevated concentrations, tamoxifen cytotoxicity becomes independent of its deleterious effects on mitochondrial function, thus injuring both glucose-and galactose-grown cells equally. Similarly, imipramine inhibits mitochondrial respiration at high concentrations (Katyare and Rajan, 1995) but also inhibits several ion channels yielding cardiotoxicity at lower concentrations (Pacher and Kecskemeti, 2004) . That both glucose-and galactose-grown cells respond similarly to imipramine argues that cytotoxicity due to inhibition of ion channels preempts the mitochondrial instability induced at higher concentrations. Doxorubicin intercalates into DNA thereby preventing its replication, but it also damages mitochondria via redox cycling that results in selective cardiotoxicity (Wallace and Starkov, 2000) . Such selective doxorubicin cardiotoxicity is likely due to an atypically outward-facing exogenous NADH dehydrogenase associated with complex I of heart mitochondria that is not found in other cells, including HepG2 lines (Gille and Nohl, 1997) . Indeed, conditions that yield robust superoxide production via autoxidation of doxorubicin semiquinone (DQ Á ) in isolated cardiac mitochondria, fail to do so in isolated liver mitochondria (Gille and Nohl, 1997) . The main metabolite of DQ Á , 7-deoxyadriamycinol aglycone, is readily detected in heart mitochondria where rotenone almost triples its production but is almost completely absent in liver mitochondria where rotenone has no effect on its production (Gille and Nohl, 1997) . These data indicate that, unlike in the heart, in the liver only a very small fraction, if any, of the observed cytotoxicity of doxorubicin is associated with mitochondrial respiration. As such, it is not surprising that doxorubicin is equally cytotoxic to glucose-and galactose-grown HepG2 cells. It would be instructive to determine whether HL-1, or other cardiac cell lines, would respond to galactose treatment like HepG2 cells and correspondingly exacerbate doxorubicin toxicity that is fueled by mitochondrial respiration. In this context, differences in susceptibility between glucose and galactose-grown cells help illuminate whether mitochondrial impairment is a primary contributor to the etiology of organ pathology or a secondary reflection of other deleterious pathways. For example, the mitochondrial toxicants rotenone, antimycin, oligomycin, and FCCP all reduce ATP more effectively in galactose-grown than glucose-grown cells (Fig. 3) . A similar response is seen with flutamide, nefazadone, fenofibrate, and nimodipine, all of which inhibit respiratory complex I. Conversely, tamoxifen, imipramine, and doxorubicin are equally toxic to both aerobically and anaerobically poised cells, which as noted above suggests that toxicity is via pathways only secondarily entailing mitochondrial dysfunction, if at all.
When combined with data from isolated mitochondria and whole-cell respiration analysis, data from glucose-and galactosegrown cells provide a comprehensive toxicity screen that also yields mechanistic insight. For example, detecting druginduced mitochondrial dysfunction in isolated organelles, or via cell respiration studies, does not necessarily mean that this is the primary source of toxicity in vivo. However, when organelle and respiration findings translate into cytotoxicity in galactose-grown, but not glucose-grown, cells, the inference that mitochondrial toxicity is the dominant pathway is justified. Conversely, if glucose-grown cells are equally susceptible to the mitochondrial toxin, then alternative toxic pathways are likely predominant.
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It should be noted that antivirals and antibiotics that target prokaryotic DNA replication or expression are unlikely to be detected in a brief 24-h toxicity assay, as was used here. Most cells contain hundreds or even thousands of mitochondria in a dynamic equilibrium between a reticulum and individual organelles (Scheffler, 1999) . Because of this redundancy, mitochondrial turnover rates for most cells (~1-2 weeks), and physiological scope, impeding mitochondrial replication is unlikely to become apparent in cell-based functional assays until after several days. In addition, HepG2 cells also lack some biotransformation capabilities. For example, mRNA copies of CYP1A1 and CYP2D6 are comparable to those in human hepatocytes, whereas CYP3A4 is literally undetectable (Wilkening et al., 2003) . We are now investigating whether exogenous recombinant CYPs, or overexpression of particular CYP isoforms, will improve detection of compounds that require bioactivation before inducing mitochondrial toxicity (Vignati et al., 2005) . It should also be noted that this method to shift metabolic poise can be applied to other cell types. The adaptation period will vary with cell type and is partly dictated by whether transcriptional events are required. Measurement of transcriptional and biochemical end points will define the rate and stability of response in the cell line under investigation.
In summary, detection of drug-induced mitochondrial toxicity, particularly using viability assays, is optimally done with cells that rely on OXPHOS for survival. Standard high-glucose culture techniques yield glycolytically poised cells that are relatively resistant to mitochondrial perturbations. Substituting galactose for glucose in the media is an expeditious way to shift metabolic poise toward OXPHOS, thereby increasing the sensitivity of cell-based models to reveal mitochondrial dysfunction.
